With commercial insurance: LEQVIO Co-Pay Program — as little as $0, a yearly max that is not published on current terms (last published $3,600 a year). With Medicare: the Leqvio card can’t be used. TotalAssist (Patient Advocate Foundation) – Hypercholesterolemia is open as of September 28, 2026.
See what this patient owes after assistance →
4 assistance programs for Leqvio patients · 3 open today
One manufacturer copay card, commercial insurance only, covering the drug but not the 96372 administration charge. A separate Novartis foundation ships Leqvio free to eligible uninsured patients.
Select the patient's insurance to see which programs may apply.
Current status · Award amounts · Eligibility · Direct application links October 12, 2026
Checked September 28, 2026 · Source 1 ↗ · Source 2 ↗
Checked September 28, 2026 · Source 1 ↗ · Source 2 ↗
Leqvio’s card can’t be used with Medicare. These funds may help. They open and close with donations, so call before telling a Leqvio patient no.
Checked September 28, 2026 · Source 1 ↗ · Source 2 ↗
Leqvio · Hypercholesterolemia · Commercial insurance
Eligible patients may pay $0
Example · Leqvio · 284 mg · 284 units · commercial plan · deductible met · 20% coinsurance · allowed amounts at the Medicare reference rate
| Without assistance | With LEQVIO Co-Pay Program (Co-pay Card, Payment Card if applicable, and Rebate) | |
|---|---|---|
| Drug responsibility | $732.55 | $0.00 |
| Administration (96372) | $3.07 | $3.07 |
| Patient owes | $735.62 | $3.07 |
Estimated patient savings: $732.55
CareCost calculates the drug and administration lines using the patient’s payer rate and benefits; this example uses the Medicare rate as a reference.
Maximum award $2,500
HealthWell Foundation fund for government-insured patients with Hypercholesterolemia (confirmed diagnosis).
Also available if this patient’s coverage falls short
Free Novartis Patient Assistance Foundation (Free Drug) for eligible patients
Change the diagnosis to see only the programs that apply to your patient.
We know of no biosimilar or same-class alternative with its own HCPCS code for Leqvio; the programs above are the only ones that apply.
Leqvio has one presentation, a 284 mg/1.5 mL prefilled syringe (NDCs 0078-1000-60 and 0078-1000-98) billed as 284 units of J1306 with modifier JZ, so there is no vial-size or draw variation to check before an assistance application.
| Task | ✓ |
|---|---|
| Find programs for this insurance type | ✓ |
| See whether each program is open | ✓ |
| See maximum award | ✓ |
| Review key eligibility requirements | ✓ |
| Open the official application | ✓ |
| Calculate cost before assistance | ✓ |
| Apply the program benefit | ✓ |
| Calculate what the patient still owes | ✓ |
Commercial insurance: Eligible commercially insured patients may qualify for the LEQVIO Co-Pay Program: $0 per dose, no income requirement. Per-treatment and yearly maximums apply; Novartis does not publish the amounts. The card covers the drug charge only, not the 96372 administration charge or the office visit, and applies to all three labeled indications: primary hypercholesterolemia (E78.00), heterozygous familial hypercholesterolemia (E78.011) and homozygous familial hypercholesterolemia (E78.010). View current program ↑
Medicare and Medicaid: The LEQVIO Co-Pay Program’s own exclusion list names Medicare, Medicaid, and other government insurance; the federal Anti-Kickback Statute is why manufacturer copay cards generally exclude federal healthcare programs, per HHS OIG guidance on copayment coupons. Two foundation funds serve hypercholesterolemia patients on Medicare instead: the PAN Foundation — Hypercholesterolemia fund, open as of August 2, 2026, up to $3,800 a year, reachable at 866-512-3861 or portal.totalassist.org; and the HealthWell Foundation - Hypercholesterolemia - Medicare Access fund at 800-675-8416 (check each fund's current status on the funds list). Both require a confirmed hypercholesterolemia diagnosis and US residency, exclude Medicaid, and cap income at 500% of the federal poverty level. PAN’s fund lists only familial hypercholesterolemia codes (E78.01, E78.010, E78.011, E78.019), so it matches HeFH billed as E78.011 or HoFH billed as E78.010, and not primary hypercholesterolemia on E78.00; HealthWell’s lists E78.00 but is closed. View current options ↑
Uninsured: Unlike the copay card, the Novartis Patient Assistance Foundation covers this product directly: free drug shipped to the provider, with no drug claim filed, for patients who are uninsured or have government insurance and meet its income guidelines. Novartis does not publish the income figures, so call the program to check. It is open; reach it at 1-800-277-2254 or pap.novartis.com. Check today’s status ↑
Why fund status matters: Manufacturer programs can change between: OPEN Accepting applications now · WAITLIST Not enrolling immediately · CLOSED Not accepting new applications. Every CareCost program card shows the status and the date it was verified.
Why the dosing schedule matters: Leqvio is billed at day 0, again at 3 months, then every 6 months: three claims in the first year, two a year after. A dose missed by less than 3 months is given on the spot and the original schedule holds; a dose missed by more than 3 months restarts the full initial-then-3-month-then-6-month cycle. Each claim needs its own program check; a status pulled at the first dose is not a guarantee it held for the second.
Yes. The LEQVIO Co-Pay Program is Novartis’s current manufacturer copay program. Eligible commercially insured patients pay as little as $0, with no income requirement. Per-treatment and yearly maximums apply; Novartis does not publish the amounts. The card covers the drug charge only, not the 96372 administration charge or the office visit. Apply on Leqvio.com ↗ or call 1-833-537-8462. Calculate cost with the program →
No. The LEQVIO Co-Pay Program’s own exclusion list names Medicare, Medicaid, and other government insurance. Two foundation funds serve hypercholesterolemia patients on Medicare instead: the PAN Foundation — Hypercholesterolemia fund, open as of August 2, 2026, up to $3,800 a year, at 866-512-3861 or portal.totalassist.org; and the HealthWell Foundation - Hypercholesterolemia - Medicare Access fund at 800-675-8416 (check each fund's current status on the funds list). Both require a confirmed hypercholesterolemia diagnosis, exclude Medicaid, and cap income at 500% of the federal poverty level. PAN’s fund lists only familial hypercholesterolemia codes, so it matches HeFH billed as E78.011 or HoFH billed as E78.010, not primary hypercholesterolemia on E78.00. Check current options ↑
Yes. The Novartis Patient Assistance Foundation ships Leqvio to the provider free of charge for eligible uninsured patients; no drug claim is filed. The record sets the income limit at 250–500% of the federal poverty level depending on household size and lists the program open as of April 9, 2026. Apply at pap.novartis.com or call 800-277-2254. Check today’s status ↑
Data current: programs verified Oct 12, 2026
LEQVIO Co-Pay Program · Novartis Patient Assistance Foundation (Free Drug) · HealthWell Foundation — Hypercholesterolemia - Medicare Access · PAN Foundation — Hypercholesterolemia. Every program links directly to its official source or application page.
Last program check: .
Reviewed September 22, 2026 by Erin Rose, CareCost Estimate founder. Methodology →
CareCost